Wataru Nogami
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Wataru Nogami has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Azumi Ueyama
Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
36 shared publications - Hisashi Wada
Department of Gastroenterological Surgery, Graduate School of Medicine, The University of Osaka, Suita, Japan
36 shared publications - Michinari Hirata
Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
36 shared publications - Morio Nagira
Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
36 shared publications - Naganari Ohkura
Department of Frontier Research in Tumor Immunology, Graduate School of Medicine, The University of Osaka, Osaka, Japan
36 shared publications - Ryohei Nagai
Pharmaceutical Research Division, Shionogi & Co., Ltd., Osaka, Japan
36 shared publications
Latest Publications
- Open Access
- 3 September 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (9) , e70332
Semi‐Mechanistic Modeling of S‐531011, a Humanized Anti‐ CCR8 Monoclonal Antibody, for Prediction of CCR8 Receptor Occupancy in Human Tumor Tissues
Semi‐mechanistic modeling approaches could be useful for optimal dose selection, and one of the approaches is pharmacokinetic (PK)/receptor occupancy (RO) model for monoclonal antibodies. This study aimed to develop a semi‐mechanistic PK/RO model of S‐531011, a humanized monoclonal antibody against human CCR8 and under development for the treatment of solid tumors, in order to predict human RO values in tumor tissues which are not available in the ongoing clinical study. The model consists of three compartments (central, peripheral, and tumor) and includes four compartments (S‐531011, CCR8, and complexes 1/2 within each compartment). The model parameters were set using available clinical data, non‐clinical data, and physiological information. The human PK/RO model was developed by refinement of a mouse PK/RO model. The time courses of RO values in the tumor compartment were simulated using the model, together with a conservative condition of slow transfer of S‐531011 from blood to the tumor. It was predicted that the RO value in the tumor compartment at 21 days (trough after the third dose after administration of S‐531011 80 mg) would be maintained at > 90% under typical model assumptions. Under the conservative condition, the RO value in the tumor after administration of S‐531011 800 mg would remain at > 90%. The developed semi‐mechanistic PK/RO model could predict human RO values of S‐531011 in tumor tissues. Under typical model assumptions, simulations suggested the dose range of 80–800 mg of S‐531011 every 3 weeks would achieve > 90% RO in tumor tissues.
- 3 September 2026
- Published by Wiley in CPT: Pharmacometrics & Systems Pharmacology
- Vol. 15 (9) , e70332
Open AccessSemi‐Mechanistic Modeling of S‐531011, a Humanized Anti‐ CCR8 Monoclonal Antibody, for Prediction of CCR8 Receptor Occupancy in Human Tumor Tissues
Semi‐mechanistic modeling approaches could be useful for optimal dose selection, and one of the approaches is pharmacokinetic (PK)/receptor occupancy (RO) model for monoclonal antibodies. This study aimed to develop a semi‐mechanistic PK/RO model of S‐531011, a humanized monoclonal antibody against human CCR8 and under development for the treatment of solid tumors, in order to predict human RO values in tumor tissues which are not available in the ongoing clinical study. The model consists of three compartments (central, peripheral, and tumor) and includes four compartments (S‐531011, CCR8, and complexes 1/2 within each compartment). The model parameters were set using available clinical data, non‐clinical data, and physiological information. The human PK/RO model was developed by refinement of a mouse PK/RO model. The time courses of RO values in the tumor compartment were simulated using the model, together with a conservative condition of slow transfer of S‐531011 from blood to the tumor. It was predicted that the RO value in the tumor compartment at 21 days (trough after the third dose after administration of S‐531011 80 mg) would be maintained at > 90% under typical model assumptions. Under the conservative condition, the RO value in the tumor after administration of S‐531011 800 mg would remain at > 90%. The developed semi‐mechanistic PK/RO model could predict human RO values of S‐531011 in tumor tissues. Under typical model assumptions, simulations suggested the dose range of 80–800 mg of S‐531011 every 3 weeks would achieve > 90% RO in tumor tissues.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S1 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
The binding activity of S-531011 against various chemokine receptors, PD-1, PD-L1, CTLA4, or mouse CCR8
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
The binding activity of S-531011 against various chemokine receptors, PD-1, PD-L1, CTLA4, or mouse CCR8
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S4 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Binding profile of the newly created CCR8 antibody
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Binding profile of the newly created CCR8 antibody
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S5 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
In vivo anti-tumor activity of S-531011 in CT26.WT or EMT6 tumor-bearing mice model.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S2 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Generation of humanized CCR8 KI mice
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Generation of humanized CCR8 KI mice
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Figure S3 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Concentration of S-531011 in serum and tumor after a single intravenous administration of S-531011 in CT26.WT tumor-bearing hCCR8 KI mice.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Concentration of S-531011 in serum and tumor after a single intravenous administration of S-531011 in CT26.WT tumor-bearing hCCR8 KI mice.
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti–PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from S-531011, a Novel Anti-Human CCR8 Antibody, Induces Potent Antitumor Responses through Depletion of Tumor-Infiltrating CCR8-Expressing Regulatory T Cells
Although regulatory T cells (Treg) are inhibitory immune cells that are essential for maintaining immune homeostasis, Tregs that infiltrate tumor tissue promote tumor growth by suppressing antitumor immunity. Selective reduction of tumor-infiltrating Tregs is, therefore, expected to activate antitumor immunity without affecting immune homeostasis. We previously reported that selective Treg depletion targeted by a C-C motif chemokine receptor 8 (CCR8) resulted in induction of strong antitumor immunity without any obvious autoimmunity in mouse models. Thus, herein, we developed a novel humanized anti-CCR8 monoclonal antibody, S-531011, aimed as a cancer immunotherapy strategy for patients with cancer. S-531011 exclusively recognized human CCR8 among all chemokine receptors and showed potent antibody-dependent cell-mediated cytotoxicity activity toward CCR8+ cells and neutralization activity against CCR8-mediated signaling. We observed that S-531011 reduced tumor-infiltrating CCR8+ Tregs and induced potent antitumor activity in a tumor-bearing human-CCR8 knock-in mouse model. Moreover, combination therapy with S-531011 and anti-mouse programmed cell death 1 (PD-1) antibody strongly suppressed tumor growth compared with anti–PD-1 antibody alone with no observable adverse effects. S-531011 also depleted human tumor-infiltrating Tregs, but not Tregs derived from human peripheral blood mononuclear cells. These results suggest that S-531011 is a promising drug for inducing antitumor immunity without severe side effects in the clinical setting.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S3 from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
Concentration of S-531011 in serum and tumor after a single intravenous administration of S-531011 in CT26.WT tumor-bearing hCCR8 KI mice.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
Concentration of S-531011 in serum and tumor after a single intravenous administration of S-531011 in CT26.WT tumor-bearing hCCR8 KI mice.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Figure S2 from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
Generation of humanized CCR8 KI mice
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S2 from S-531011, a novel anti-human CCR8 antibody, induces potent anti-tumor responses through depletion of tumor-infiltrating CCR8-expressing regulatory T cells
Generation of humanized CCR8 KI mice